Batea Oncology is developing targeted therapeutic solutions for aggressive cancers characterized by low survival rates, utilizing advanced drug delivery systems and biomarker-driven approaches. The company focuses on improving patient outcomes by enhancing treatment efficacy and minimizing side effects in challenging oncological cases.
Funding
Funding not disclosed
Founders
Product
Problem
Glioblastoma, the most common and aggressive primary brain tumor, has a high recurrence rate (90%) and a low 5-year survival rate (<5%) despite standard treatment involving surgery and chemoradiotherapy. Resection surgery is often incomplete, leaving residual cancer cells that infiltrate the brain tissue and are highly resistant to radiotherapy. The standard of care for glioblastoma has remained largely unchanged for the last 20 years.
Solution
Batea Oncology is developing GlioHook, a Class III medical device designed to improve outcomes for glioblastoma patients by addressing the limitations of current treatments. GlioHook is implanted post-resection to concentrate remaining tumor cells in a controlled location, effectively changing the disease from an infiltrative to a focalized one. This focalization renders the cancer cells more sensitive to subsequent radiotherapy, creating a new treatment paradigm by combining disease focalization and radio-sensitization. GlioHook is designed to be easily integrated into the current standard of care, taking advantage of the therapeutic window between surgery and radiotherapy.
Target Audience
The primary target audience includes neurosurgeons and medical oncologists specializing in glioblastoma treatment, as well as hospitals and cancer centers focused on improving patient survival rates for aggressive cancers.
Features
- Class III medical device implanted post-resection surgery.
- Concentrates residual tumor cells to focalize the disease.
- Increases sensitivity of cancer cells to radiotherapy.
- Designed for seamless integration with existing standard of care.
- Addresses the therapeutic gap between surgery and radiotherapy.
- Easily scalable for manufacturing.